Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2

スポンサーリンク

概要

• 論文の詳細を見る

• Lysophosphatidic acid (LPA) is one of the simplest natural phospholipids. This phospholipid is recognized as an extracellular potent lipid mediator with diverse effects on various cells. Although LPA is shown to stimulate proliferation and motility via LPA receptors, LPA1 and LPA2, in several cancer cell lines, the role of LPA and LPA receptors for malignant pleural mesothelioma (MPM) has been unknown. MPM is an aggressive malignancy with a poor prognosis and the incidence is increasing and is expected to increase further for another 10-20 years worldwide. Therefore, the development of novel effective therapies is needed urgently. In this study, we investigated the effect of LPA on the proliferation and motility of MPM cells. We found that all 12 cell lines and four clinical samples of MPM expressed LPA1, and some of them expressed LPA2, LPA3, LPA4 and LPA5. LPA stimulated the proliferation and motility of MPM cells in a dose-dependent manner. Moreover, LPA-induced proliferation was inhibited by Ki16425, an inhibitor of LPA1, and small interfering RNA against LPA1, but not LPA2. Interestingly, LPA-induced motility was inhibited by small interfering RNA against LPA2, but not LPA1, unlike a number of previous reports. These results indicate that LPA is a critical factor on proliferation though LPA1, and on motility though LPA2 in MPM cells. Therefore, LPA and LPA receptors, LPA2 as well as LPA1, represent potential therapeutic targets for patients with MPM. © 2008 Japanese Cancer Association.

• 日本癌学会の論文
• 2008-08-10

著者

• YANO Seiji

  Department of Internal Medicine and Molecular Therapeutics, The University of Tokushima Graduate Sch

• SONE Saburo

  Department of Internal Medicine and Molecular Therapeutics, The University of Tokushima Graduate Sch

• TANIGUCHI Tetsuo

  Division of Molecular Oncology, Aichi Cancer Center Research Institute

• SEKIDO Yoshitaka

  Division of Molecular Oncology, Aichi Cancer Center Research Institute

• Yano Seiji

  The Third Department Of Internal Medicine Tokushima University School Of Medicine

• KANEMATSU Takanori

  Department of Chest Surgery, National Kyushu Cancer Center

• Tsuruo Takashi

  Division Of Molecular Oncology Aichi Cancer Center Research Institute

• Sekido Yoshitaka

  Division Of Molecular Oncology Aichi Cancer Center Research Institute

• YAMADA Tadaaki

  Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, Univers

• OGINO Hirokazu

  Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, Univers

• IKUTA Kenji

  Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, Univers

• KAKIUCHI Soji

  Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, Univers

• HANIBUCHI Masaki

  Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, Univers

• Tsuruo Takashi

  The Cancer Chemotherapy Center Japanese Foundation For Cancer Research (jfcr)

• Yano Seiji

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences Universit

• Tsuruo T

  Division Of Molecular Oncology Aichi Cancer Center Research Institute

• Ikuta Kenji

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences Universit

• Sone S

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences Universit

• Kakiuchi Soji

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences Universit

• Tsuruo T

  The Cancer Chemotherapy Center Japanese Foundation For Cancer Research (jfcr)

• Ogino Hirokazu

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences Universit

• Yamada Tadaaki

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences Universit

• Tsuruo T

  Japanese Foundation For Cancer Research Tokyo Jpn

• YAMADA Tadaaki

  Kanazawa University Hospital Cancer Center

• Yano S

  Department Of Internal Medicine And Molecular Therapeutics University Of Tokushima School Of Medicin

• Yano Seiji

  The Third Department Of Internal Medicine The University Of Tokushima School Of Medicine

• Kanematsu Takanori

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences Universit

• Hanibuchi M

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences Universit

• Sone Saburo

  Department Of Internal Medicine And Molecular Therapeutics Institute Of Health Biosciences The Unive

• Yano Seiji

  Department Of Internal Medicine And Molecular Tharapeutics University Of Tokushima School Of Medicin

• Sato Shigeo

  The Cancer Chemotherapy Center Japanese Foundation For Cancer Research

• KANEMATSU Takanori

  Department of Internal Medicine and Molecular Therapeutics, Institute of Health Biosciences, University of Tokushima Graduate School

• Ikuta Kenji

  Department of Electronic Device Engineering, Graduate School of Information Science and Electrical Engineering, Kyushu University

• SONE Saburo

  Department of Internal Medicine and Molecular Tharapeutics, University of Tokushima School of Medicine

• Taniguchi Tetsuo

  The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research (JFCR)

関連論文

• The Novel Src Kinase Inhibitor M475271 Inhibits VEGF-Induced Vascular Endothelial-Cadherin and β-Catenin Phosphorylation but Increases Their Association
• A Novel Src Kinase Inhibitor, M475271, Inhibits VEGF-Induced Human Umbilical Vein Endothelial Cell Proliferation and Migration
• Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer
• Decreased Synthesis of Matrix Metalloproteinase-7 and Adhesion to the Extracellular Matrix Proteins of Human Colon Cancer Cells Treated with Troglitazone
• The Soy Isoflavone Equol Enhances Antigen-Specific IgE Production in Ovalbumin-Immunized BALB/c Mice
• Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32
• EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification
• Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients
• Treatment Outcome of Resected and Nonresected Primary Adenoid Cystic Carcinoma of the Lung
• TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling
• Involvement of mitochondrial aggregation in arsenic trioxide (As_2O_3)-induced apoptosis in human glioblastoma cells
• MOLECULAR TARGETING THERAPY OF CANCER : DRUG RESISTANCE, APOPTOSIS AND SURVIVAL SIGNAL
• Molecular targeting therapy of cancer : drug resistance, apoptosis and survival signal
• Mitochondria regulate the unfolded protein response leading to cancer cell survival under glucose deprivation conditions
• Preventing the unfolded protein response via aberrant activation of 4E-binding protein 1 by versipelostatin
• Expressions of Cell Cycle Regulators in Human Colorectal Cancer Cell Lines
• Effect of Circulating Antigen on Immunoscintigraphy of Ovarian Cancer Patients Using Anti-CA125 Monoclonal Antibody
• Multfunctional interleukin-1β promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules
• A New Quinoline Derivative MS-209 Reverses Multidrug Resistance and Inhibits Multiorgan Metastases by P-glycoprotein-expressing Human Small Cell Lung Cancer Cells
• Genetic Polymorphisms of the UDP-Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer Patients
• Infrequent Mutation of the hBUB1 and hBUBR1 Genes in Human Lung Cancer
• POTENTIATION OF CHEMOTHERAPEUTIC EFFECT OF VINCRISTINE IN VINCRISTINE RESISTANT TUMOR BEARING MICE BY CALMODULIN INHIBITOR CLOMIPRAMINE
• ANTITUMOR EFFICACIES OF ACLACINOMYCIN A BY ORAL ADMINISTRATION
• Structure-antitumor Activity Relationship of Semi-synthetic Spicamycin Derivatives
• Synthesis and Antitumor Activities of Glycine-exchanged Analogs of Spicamycin
• Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas
• Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2
• Combination Therapy with Antibody and Interleukin-2 Gene Transfer against Multidrug-resistant Cancer Cells
• Transduction of the Macrophage Colony-stimulating Factor Gene into Human Multidrug Resistant Cancer Cells : Enhanced Therapeutic Efficacy of Monoclonal Anti-P-glycoprotein Antibody in Nude Mice
• Molecular biology of malignant mesothelioma
• SUCCESSFULLY PERFORMED PYLORUS PRESERVING PANCREATODUODENECTOMY FOR AMPULLARY CARCINOMA ASSOCIATED WITH CELIAC AXIS OCCLUSION
• Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity
• Immunological Quantitation of DT-Diaphorase in Carcinoma Cell Lines and Clinical Colon Cancers : Advanced Tumors Express Greater Levels of DT-Diaphorase
• Acute Induction of Adriamycin-resistance in Human Colon Carcinoma HT-29 Cells Exposed to a Sublethal Dose of Adriamycin
• Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor
• Current status and perspective of angiogenesis and antivascular therapeutic strategy : non-small cell lung cancer
• MOLECULAR MECHANISMS OF ANGIOGENESIS IN NON-SMALL CELL LUNG CANCER, AND THERAPEUTICS TARGETING RELATED MOLECULES
• Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules
• A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa"^1)
• Angiogenesis in the Progression of Lung Cancer
• Symposium on Molecular Pathogenesis of Respiratory Diseases and Its Clinical Implication, Molecular Pathogenesis of Lung Cancer and Its Molecular Targeted Therapy
• Synchronous small cell carcinoma and adenocarcinoma of the lung representing different retinoblastoma tumor suppressor protein status
• An Autopsy Case of Cytokeratin 7-positive Minute Adenocarcinoma of the Lung with Systemic Metastases
• The role of cyclosporin A on anitibody-dependent monocyte-mediated cytotoxicity against human multidrug-resistant cancer cells
• Induction by Interleukin-15 of Human Killer Cell Activity against Lung Cancer Cell Lines and Its Regulatory Mechanisms
• Anti-ganglioside GM_2 Monoclonal Antibody-dependent Killing of Human Lung Cancer Cells by Lymphocytes and Monocytes
• Inhibition of Tumor Cell Invasion and Matrix Degradation by Aminopeptidase Inhibitors
• A NOVEL ANTITUMOR CYCLIC HEXAPEPTIDE (RA-700) OBTAINED FROM RUBIAE RADIX
• Large renal aneurysm successfully treated by percutaneous embolization using detachable steel coils
• Necessity of Preoperative Screening for Brain Metastasis in Non-small Cell Lung Cancer Patients without Lymph Node Metastasis
• Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis
• Inhibitory Effect of ATF3 Antisense Oligonucleotide on Ectopic Growth of HT29 Human Colon Cancer Cells
• Analysis of Novel Metastasis-associated Gene TI-227
• Evaluation of Antivascular and Antimitotic Effects Tubulin Binding Agents in Solid Tumor Therapy
• A Novel Combretastatin A-4 Derivative, AC-7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors
• Inhibitory effects of n-3 polyunsaturated fatty acids on sigmoid colon cancer transformants
• Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export
• Acyl-CoA synthetase as a cancer survival factor : its inhibition enhances the efficacy of etoposide
• Soluble Fas in malignant pleural effusion and its expression in lung cancer cells
• Localized pleural malignant mesothelioma
• Anaplastic large-cell lymphoma (Ki-1 lymphoma) : ultrastructural and immunohistochemical studies
• Estrone and 17β-Estradiol Reverse Breast Cancer Resistance Protein-mediated Multidrug Resistance
• Identification and Characterization of a Deletion Mutant of DNA Topoisomerase I mRNA in a Camptothecin-resistant Subline of Human Colon Carcinoma
• Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib
• Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells
• Transforming growth factor β stimulates rheumatoid synovial fibroblasts via the type II receptor
• Soy Isoflavone Equol Perpetuates Dextran Sulfate Sodium-Induced Acute Colitis in Mice
• Intrapulmonary solitary fibrous tumor
• 6. Angiogenesis in the Progression of Lung Cancer
• Multifunctional interieukin-1 beta promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasion- and angiogenesis-related molecules
• 134 DIAGNOSIS OF AN AUTOIMMUNE NEUTROPENIA CASE DURING GROWTH HOERMONE ADMINISTRSTION
• Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules
• The Novel Src Kinase Inhibitor M475271 Inhibits VEGF-Induced Vascular Endothelial-Cadherin and β-Catenin Phosphorylation but Increases Their Association
• Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells
• Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies

もっと見る 閉じる

スポンサーリンク